The P2X3 antagonists are the furthest along in the drug development process, but there are other potential drugs being evaluated to treat chronic cough, which currently has no FDA-approved therapies on the market, said Peter Dicpinigaitis, MD, chair of the American Cough Conference.
The P2X3 antagonists are the furthest along in the drug development process, but there are other potential drugs being evaluated to treat chronic cough, which currently has no FDA-approved therapies on the market, said Peter Dicpinigaitis, MD, chair of the American Cough Conference, professor of medicine at the Albert Einstein College of Medicine, director of the Montefiore Cough Center, and editor-in-chief of LUNG.
Transcript
There are a number of P2X3 antagonists being studied for chronic cough: What is it about these drugs that they seem to be promising in the treatment of chronic cough?
So, it's nice for me to be able to say that the last 5 or 10 years in the cough world have been very exciting ones because we have gone from having really no chronic cough drugs ever approved in the United States, which is the case, to now having a number of promising drugs in the pipeline.
And the most exciting and the most far advanced of these are, as you mentioned, the P2X3 antagonists. The P2X3 ion channels or receptors lie in the airway, and they are triggered by intra-airway ATP. So, we have learned in the last few years that this is a very important mechanism for the production of cough.
So, once we established that the P2X3 receptor is an important component of the mechanism of cough induction, then P2X3 antagonists were developed to block that initiation of that afferent cough reflex. In fact, we have 4 drugs in the pipeline now, one of which, gefapixant, has actually completed phase 3 trials, and that drug is furthest along. But there are 3 other companies with their own P2X3 antagonists, which are felt to be possibly more specific P2X3 antagonists. So, we will have updated lectures from all 4 of the companies in the P2X3 space giving us the most up-to-date data on their studies: 1 in phase 3, and 3 in phase 2.
Although the P2X3 programs are by far the most far along in terms of clinical development, the P2X3 antagonists aren't the only potential drugs being looked at. There are 2 other exciting programs going on looking at a neurokinin-1, or NK-1, receptor antagonist. These drugs could have peripheral and central effects against cough.
And earlier on in the pipeline but very interesting too are the so-called voltage-gated sodium channel blockers or the Nav1.7 blockers, which have a mechanism similar to lidocaine, for example, but are more specific to the cough reflex. So, we're greatly looking forward to learning more about how those drug programs go on in the coming years.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More